About this trial
When vessel wall injury occurs, platelets become activated, releasing more than 30 bioactive proteins, many of which have a fundamental role in hemostasis, inflammation and ultimate wound healing. Platelet-rich plasma (PRP), a modification of fibrin glue made from autologous blood, is being used to deliver growth factors in high concentration to sites requiring wound healing. PRP is obtained from a sample of patients' blood drawn at the time of treatment. As the rate of cesarean deliveries has been rising, long-term adverse sequelae due to uterine scar defects have been increasing. PRP might be a simple preventive treatment that potentially can reduce morbidity following cesarean deliveries.
Eligibility criteria
Qualifiers
Women undergoing elective cesarean delivery
Term pregnancy (≥37 weeks of gestation)
Disqualifiers
Thrombocytopenia (CBC Platelet count <70,000)
Connective tissue disease
Uterine scars other than cesarean (s/p myomectomy, s/p cornual resection)
Malformed uterus (unicornuate, bicornuate, didelphic)
Trial design
Treatments tested in this trial
- Platelet Rich Plasma
- Placebo
Treatment groups
Sponsors and collaborators
The University of Texas Health Science Center, Houston
Lead sponsor
Sheba Medical Center
Collaborator